



bioMérieux – First-Quarter 2026 Business Review

- **First quarter was impacted by mild respiratory epidemiology, and by the uncertain geopolitical and macroeconomic environment which drives softness in customers' investment decisions.**
- **-3.9% organic sales decline in Q1 2026, reflecting a weaker respiratory season compared with the exceptionally strong epidemiology in Q1 2025 (resulting in BIOFIRE^{®1} respiratory panels sales down 23%) and a slow start of the year in instruments sales (-18%) in a soft market for new installations.**
- **GO•28 growth drivers' reagents sales up 6.5% organically, notably +31% in SPOTFIRE^{®2} reagents sales and +8% in industrial applications reagents sales.**
- **Considering the first-quarter performance and the current market dynamics, bioMérieux revises its 2026 full-year guidance:**
 - **Annual sales are now expected to grow organically between +3% to +5% (versus between +5% and +7% previously);**
 - **Annual CEBIT³ is expected to grow organically between 0% and 10% (versus at least +10% previously) excluding a prolonged impact of Middle East events.**
- **Confirmation of a full-year CEBIT headwind from currency effect³ of -€50m to -€60m.**

Pierre Boulud, Chief Executive Officer, said: *"In Q1 26, we continued to deliver on innovation, with the launch of SPOTFIRE[®] mini assays in Europe, the regulatory filing of SpinChip Hs-troponin assay, the launch of Mycoplasma assay on SPOTFIRE[®], and the acquisition of Accellix for Pharma Quality Control. For 2026, acknowledging the particularly soft market environment that weighed on first-quarter performance, bioMérieux has revised its full-year guidance downward. Leveraging our GO•28 initiatives, we will maintain strict and disciplined control of our cost base, to ensure a positive organic evolution of CEBIT in 2026."*

¹ In this press release BIOFIRE[®] refers to BIOFIRE[®] FILMARRAY[®] TORCH system and panels

² In this press release SPOTFIRE[®] refers to BIOFIRE[®] SPOTFIRE[®] system and panels

³ As defined in Appendix #1

Marcy l'Étoile (France), April 23rd, 2026 – bioMérieux, a world leader in the field of *in vitro* diagnostics, today releases its business review for the three months ended March 31, 2026.

SALES

Note: Unless otherwise stated, growth is expressed year-on-year at constant exchange rates and scope of consolidation (like-for-like).

Consolidated sales totaled €984 million in the first quarter of 2026, down 10.4% as reported from €1,098 million in first quarter of 2025. Organic growth (at constant exchange rates and scope of consolidation) stood at -3.9%. Currency effect had a negative impact of €73 million over the first quarter sales, mainly due to the depreciation of the US dollar against the euro.

Analysis of sales

In € millions

SALES – THREE MONTHS ENDED MARCH 31, 2025	1,098	
Currency effect	-73	-6.6%
Changes in scope of consolidation ⁴ and hyperinflation ⁵	1	0.1%
Organic growth (at constant exchange rates and scope of consolidation)	-43	-3.9%
SALES – THREE MONTHS ENDED MARCH 31, 2026	984	-10.4%

ANALYSIS OF SALES BY APPLICATION

Sales by Application In € millions	Q1 2026	Q1 2025	% change as reported	% change at constant exchange rates and scope of consolidation
Clinical Applications	824.5	937.8	-12.1%	-5.5%
Molecular biology	424.8	521.7	-18.6%	-11.1%
BIOFIRE	357.6	452.2	-20.9%	-13.8%
SPOTFIRE	56.0	54.3	+3.2%	+14.5%
Other molecular	11.2	15.2	-26.8%	-23.1%
Microbiology	314.9	326.1	-3.4%	+2.0%
Immunoassays	67.1	75.0	-10.6%	-5.4%
Other lines ⁽¹⁾	17.8	14.9	+19.6%	+26.8%
Industrial Applications⁽²⁾	159.1	160.1	-0.6%	+5.2%
TOTAL SALES	983.6	1,097.9	-10.4%	-3.9%

(1) Including mainly BioFire Defense, R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

Q1 2026 vs Q1 2025 like-for-like trends per application:

- **Clinical applications sales** (84% of total sales), decreased by 5% to €825 million in the first quarter of 2026.
 - In **molecular biology**:
 - BIOFIRE® respiratory panels sales declined by 23%, mainly reflecting lower testing volumes due to a low respiratory epidemiology, compared with very strong respiratory activity in Q1 2025.
 - BIOFIRE® non-respiratory panels delivered 4% sales growth, driven by double-digit growth in Blood Culture Identification (BCID) and Joint Infection (JI) panels sales. This was partly offset by a softer-

⁴ As defined in Appendix #2.

⁵ For those currencies meeting the criteria to be considered hyperinflationary under IAS 29, such as Argentina and Turkey, an IFRS technical adjustment for hyperinflation impact is reflected as FX and therefore excluded from the organic growth calculation. The effect of operational actions taken in these countries such as increased pricing to mitigate the inflationary impact is reflected as part of the organic growth

- than-expected performance of Pneumonia (-2%, reflecting the very mild respiratory season) and Meningitis panels, while the installed base continued to expand during the quarter.
- SPOTFIRE® sales reached €56m, up 15%, despite the very low respiratory season compared with the 1st quarter of 2025. Reagents sales increased by 31% while instrument sales were negatively impacted by a high comparison base in Japan where Q1 2025 benefited from a one-time public funding scheme. The installed base grew by 450 instruments, exceeding 6,800 units at the end of March 2026.
 - In **microbiology**, sales increased by 2% in line with expectations. Quarterly performance was still impacted by activity in China (-7%) and a soft performance in equipment sales in a challenging environment that tends to delay customers' investment decisions. Excluding China, combined BACT/ALERT® and VITEK® reagent sales grew mid-single digit.
 - In **immunoassays**, sales declined by 5%, continuing to be impacted by the decrease in global VIDAS® PCT (Procalcitonin) sales and a challenging market environment in China.
 - **Industrial applications** sales (16% of total sales) grew by 5%, supported by high single-digit growth in reagents sales, notably in blood culture, cytometry and molecular ranges. This growth was partly offset by a decline in instruments sales which reflects some customers' prudence.

ANALYSIS OF SALES BY REGION

Sales by Region In € millions	Q1 2026	Q1 2025	% change as reported	% change at constant exchange rates and scope of consolidation
North America	455.9	543.5	-16.1%	-6.9%
Latin America	68.7	62.7	+9.5%	+15.7%
EMEA ⁽¹⁾	315.9	320.7	-1.5%	-0.7%
Asia Pacific	143.1	170.9	-16.3%	-7.6%
TOTAL SALES	983.6	1,097.9	-10.4%	-3.9%

⁽¹⁾ Including Europe, the Middle East and Africa.

Q1 2026 vs Q1 2025 like-for-like trends per region:

- ▾ In **North America** (46% of total sales), revenue decreased by 7% impacted by the setback of BIOFIRE® respiratory panels sales that more than offset the double-digit growth in Industrial Applications sales and the close to 30% increase in SPOTFIRE® sales.
- ▾ In **Latin America** (7% of total sales), sales grew +16%, driven by strong molecular sales (+22%) and a double-digit growth in microbiology sales.
- ▾ Sales in the **Europe – Middle East – Africa** region (32% of total sales) totaled €316 million, a slight 1% decline. The high single digit sales growth in blood culture and in molecular biology (excluding BIOFIRE® respiratory panels) were almost entirely offset by the decline in BIOFIRE® respiratory sales.
- ▾ Sales in the **Asia Pacific** region (15% of total sales) decreased by 8%. The double-digit sales growth in India and the close to 50% increase in SPOTFIRE® reagents sales in Japan were compensated by the expected strong decline in SPOTFIRE® instrument sales in Japan (boosted in Q1 2025 by a special government funding scheme), as well as the decrease in BIOFIRE® respiratory panels sales across the region and a mid-single digit decline in sales in microbiology in China, still impacted by downward pressure on local healthcare spend in hospitals.

EVENTS OF FIRST QUARTER 2026

- ▶ **bioMérieux receives IVDR CE Marking for two SPOTFIRE® panels to strengthen near-patient respiratory and sore throat diagnostics across Europe**

In March 2026, bioMérieux announced that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/ST*plus*) Panel and BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/ST*plus*) Panel Mini have been CE-marked under the IVDR. The certification includes conformity assessment for near-patient testing, enabling its use outside traditional laboratories, directly at the point of care. These multiplex PCR tests can simultaneously detect the most common pathogens responsible for respiratory and sore throat infections, within a timeframe aligned with a typical patient visit.

- ▶ **bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality**

In February 2026, bioMérieux announced the launch of SMARTBIOME™, an innovative solution designed to help food manufacturers better understand, control and prevent microbiological spoilage. By combining high-precision DNA sequencing, advanced bioinformatics and bioMérieux's microbiology expertise, SMARTBIOME™ provides actionable insights to protect product quality, reduce waste and better preserve consumer safety.

- ▶ **bioMérieux acquires Accellix**

On January 22nd, 2026 bioMérieux acquired Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.

SUBSEQUENT EVENTS

- ▶ **bioMérieux launches the BIOFIRE® SPOTFIRE® molecular testing solution for the pharmaceutical industry, redefining rapid mycoplasma testing**

On April 9th, 2026, bioMérieux announced the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries. This platform introduces a simple, small and smart approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients.

INVESTOR PRESENTATION

bioMérieux will hold an investor presentation on Thursday, April 23, 2026 at 2:00 PM Paris time (GMT+1). The presentation will be conducted in English and will be accessible via webcast.

Webcast link: : <https://biomerieux.engagestream.euronext.com/2026-04-23-q1>

For people unable to join the webcast URL, please register to the audio conference through the link below

Audio conference link: <https://engagestream.euronext.com/biomerieux/2026-04-23-q1/dial-in>

INVESTOR CALENDAR

Annual General Meeting
First-half 2026 results
Third-quarter 2026 sales

May 28, 2026
July 28, 2026
November 3, 2026



ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 60 years, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com.

CONTACTS

Investor Relations

bioMérieux

Aymeric Fichet

Tel.: +33 (0)4 78 87 20 00

investor.relations@biomerieux.com

Media Relations

bioMérieux Corporate

Romain Duchez

Tel.: +33 (0)4 78 87 21 99

media@biomerieux.com

bioMérieux - France

Isabelle de Segonzac (Image 7)

Tel.: +33 (0)1 53 70 74 64

isegonzac@image7.fr

PRESS RELEASE

APPENDIX 1: GLOSSARY & DISCLAIMER

DEFINITIONS

Changes in the scope of consolidation:

The effects of changes in the scope of consolidation are determined:

- for acquisitions for the period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the period by the entities acquired from their entry into the scope of consolidation;
- for acquisitions of the previous period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the months in which the acquired entities were not consolidated during the previous period;
- for disposals for the period by adding to sales and operating expenses for the period the amount of sales and operating expenses made by the entities sold the previous period, during the months in which these entities are no longer consolidated over the current period;
- for disposals for the previous period, by adding to the sales and operating expenses of the period the sales and operating expenses made during the preceding period by the entities sold.

Contributive operating income before non-recurring items (CEBIT): operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs. The Company considers that this indicator provides the best possible representation of the operational performance of the Company.

Currency effect: established by comparing the actual numbers converted at the average exchange rates of the current year to the actual numbers converted at the average exchange rates of the comparative period. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up.

DISCLAIMER

The forward-looking statements contained in this document are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2025 Universal Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.